Biomarkers for Brain Disorders: Challenges and Opportunities
27 February–2 March 2011

This exciting new Wellcome Trust Scientific Conference will discuss methodological aspects of biomarker identification across a spectrum of psychiatric and neurodegenerative disorders, strategies for diagnostic assay development and pathways for regulatory approval. Specific attention will be given to results from consortia such as the Alzheimer Disease Neuroimaging Initiative (ADNI), and to the prioritization of approaches not yet included in large consortia efforts, such as functional measures of brain activity captured by fMRI or electrophysiological recordings.

Topics:
- Strategies for building large biorepositories
- Technologies for molecular profiling and biomarker discovery: is multimodality the key?
- Building and validating biochemical and functional assays
- Measuring brain function in health and disease
- Clinical studies of biomarkers in neurological disease (e.g. Amyotrophic lateral sclerosis, Multiple sclerosis, schizophrenia, Alzheimer’s, Parkinson’s disease, and other CNS indications)
- Paths for regulatory approval

Abstract deadline: 17 January 2011
Registration deadline: 24 January 2011

Courses and Conferences are held at the Wellcome Trust Genome Campus, Hinxton, Cambridge – home to one of the world’s largest concentrations of expertise in genomics and bioinformatics. For full details, please visit, www.wellcome.ac.uk/conferences